Another similar clinical case was reported by Wondergem et al., who noticed increased PSMA uptake in lymph node metastases after initiation of enzalutamide treatment, whereas lymph node volume and PSA decreased over time [34]. The gene discussed is KLK3; the disease is metastatic malignant neoplasm in the lymph nodes.